AR051524A1 - Seleccion de pacientes para una terapia con un inhibidor de her - Google Patents
Seleccion de pacientes para una terapia con un inhibidor de herInfo
- Publication number
- AR051524A1 AR051524A1 ARP050105126A ARP050105126A AR051524A1 AR 051524 A1 AR051524 A1 AR 051524A1 AR P050105126 A ARP050105126 A AR P050105126A AR P050105126 A ARP050105126 A AR P050105126A AR 051524 A1 AR051524 A1 AR 051524A1
- Authority
- AR
- Argentina
- Prior art keywords
- therapy
- inhibitor
- patient selection
- analysis
- procedure
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57449—Specifically defined cancers of ovaries
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/5748—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving oncogenic proteins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/475—Assays involving growth factors
- G01N2333/485—Epidermal growth factor [EGF] (urogastrone)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/91—Transferases (2.)
- G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
- G01N2333/91205—Phosphotransferases in general
- G01N2333/9121—Phosphotransferases in general with an alcohol group as acceptor (2.7.1), e.g. general tyrosine, serine or threonine kinases
- G01N2333/91215—Phosphotransferases in general with an alcohol group as acceptor (2.7.1), e.g. general tyrosine, serine or threonine kinases with a definite EC number (2.7.1.-)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Analytical Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Pathology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Hospice & Palliative Care (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- General Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
Se describe un procedimiento de seleccion de pacientes para una terapia con un inhibidor de HER, como el pertuzumab, sobre la base del análisis de la expresion génica. También se describe un procedimiento para evaluar la fosforilacion o activacion de HER en una muestra biologica a través del análisis de la expresion génica.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US63394104P | 2004-12-07 | 2004-12-07 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR051524A1 true AR051524A1 (es) | 2007-01-17 |
Family
ID=36177671
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP050105126A AR051524A1 (es) | 2004-12-07 | 2005-12-07 | Seleccion de pacientes para una terapia con un inhibidor de her |
Country Status (14)
Country | Link |
---|---|
US (2) | US20060121044A1 (es) |
EP (1) | EP1825001A2 (es) |
JP (1) | JP2008523073A (es) |
KR (1) | KR20070085855A (es) |
CN (1) | CN101115849A (es) |
AR (1) | AR051524A1 (es) |
AU (1) | AU2005314127A1 (es) |
BR (1) | BRPI0518086A (es) |
CA (1) | CA2587519A1 (es) |
MX (1) | MX2007006529A (es) |
NO (1) | NO20073487L (es) |
RU (1) | RU2007125644A (es) |
WO (1) | WO2006063042A2 (es) |
ZA (1) | ZA200704796B (es) |
Families Citing this family (53)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ZA9811162B (en) * | 1997-12-12 | 2000-06-07 | Genentech Inc | Treatment with anti-ERBB2 antibodies. |
CN102698265A (zh) | 2000-05-19 | 2012-10-03 | 杰南技术公司 | 用于提高对ErbB 拮抗剂癌症治疗的有效应答可能性的基因检测试验 |
US20100056762A1 (en) | 2001-05-11 | 2010-03-04 | Old Lloyd J | Specific binding proteins and uses thereof |
ATE446317T1 (de) | 2001-05-11 | 2009-11-15 | Ludwig Inst For Cancer Res Ltd | Spezifische bindungsproteine und ihre verwendung |
US7767792B2 (en) * | 2004-02-20 | 2010-08-03 | Ludwig Institute For Cancer Research Ltd. | Antibodies to EGF receptor epitope peptides |
GT200500155A (es) * | 2004-06-16 | 2006-05-15 | Terapia del càncer resistente al platino | |
KR20180091967A (ko) | 2004-07-22 | 2018-08-16 | 제넨테크, 인크. | Her2 항체 조성물 |
JO3000B1 (ar) | 2004-10-20 | 2016-09-05 | Genentech Inc | مركبات أجسام مضادة . |
WO2006063042A2 (en) * | 2004-12-07 | 2006-06-15 | Genentech, Inc. | Selecting patients for therapy with a her inhibitor |
KR20170134771A (ko) * | 2005-01-21 | 2017-12-06 | 제넨테크, 인크. | Her 항체의 고정 용량 투여법 |
KR101253576B1 (ko) * | 2005-02-23 | 2013-04-11 | 제넨테크, 인크. | Her 이량체화 억제제를 이용한 암 환자에서의 질환진행까지의 시간 또는 생존의 연장 |
PE20070207A1 (es) * | 2005-07-22 | 2007-03-09 | Genentech Inc | Tratamiento combinado de los tumores que expresan el her |
US7700299B2 (en) * | 2005-08-12 | 2010-04-20 | Hoffmann-La Roche Inc. | Method for predicting the response to a treatment |
CA2620195A1 (en) * | 2005-08-24 | 2007-03-01 | Bristol-Myers Squibb Company | Biomarkers and methods for determining sensitivity to epidermal growth factor receptor modulators |
JP2007135581A (ja) * | 2005-10-20 | 2007-06-07 | Japan Science & Technology Agency | 自己免疫性血小板減少性紫斑病(itp)患者の血液細胞特異的遺伝子群 |
US20080038271A1 (en) * | 2006-06-05 | 2008-02-14 | Amler Lukas C | Extending survival of cancer patients with elevated levels of EGF or TGF-alpha |
AU2007324868B2 (en) | 2006-11-28 | 2014-03-20 | Daiichi Sankyo Europe Gmbh | Activated HER3 as a marker for predicting therapeutic efficacy |
US7825127B2 (en) * | 2006-12-28 | 2010-11-02 | Takeda Pharmaceutical Company, Limited | Method for treating cancer |
JP5276017B2 (ja) | 2007-01-25 | 2013-08-28 | デイナ ファーバー キャンサー インスティチュート,インコーポレイテッド | Egfr変異体仲介性疾患の治療における抗egfr抗体の使用 |
EP2899541A1 (en) | 2007-03-02 | 2015-07-29 | Genentech, Inc. | Predicting response to a HER dimerisation inhbitor based on low HER3 expression |
PL2171090T3 (pl) * | 2007-06-08 | 2013-09-30 | Genentech Inc | Markery ekspresji genów odporności guza na leczenie hamujące HER2 |
US9551033B2 (en) | 2007-06-08 | 2017-01-24 | Genentech, Inc. | Gene expression markers of tumor resistance to HER2 inhibitor treatment |
CN101896503B (zh) | 2007-08-14 | 2018-05-22 | 路德维格癌症研究所有限公司 | 靶向egf受体的单克隆抗体175及其衍生物和用途 |
WO2009026705A1 (en) * | 2007-08-24 | 2009-03-05 | The University Of Western Ontario | Method of diagnosing and treating osteoarthritis |
TWI472339B (zh) | 2008-01-30 | 2015-02-11 | Genentech Inc | 包含結合至her2結構域ii之抗體及其酸性變異體的組合物 |
BRPI0812682A2 (pt) | 2008-06-16 | 2010-06-22 | Genentech Inc | tratamento de cáncer de mama metastático |
CA2729796C (en) | 2008-07-08 | 2017-07-04 | George Mason Intellectual Properties, Inc. | Phosphorylated c-erbb2 as a superior predictive theranostic marker for the diagnosis and treatment of cancer |
EP2362783A2 (en) | 2008-10-31 | 2011-09-07 | Biogen Idec MA Inc. | Light targeting molecules and uses thereof |
EP2513148B1 (en) * | 2009-12-16 | 2016-08-31 | AbbVie Biotherapeutics Inc. | Anti-her2 antibodies and their uses |
US8895001B2 (en) | 2010-03-11 | 2014-11-25 | Merrimack Pharmaceuticals, Inc. | Use of ErbB3 inhibitors in the treatment of triple negative and basal-like breast cancers |
EP2576621B1 (en) | 2010-05-27 | 2019-04-10 | Genmab A/S | Monoclonal antibodies against her2 |
EP2575880B1 (en) | 2010-05-27 | 2019-01-16 | Genmab A/S | Monoclonal antibodies against her2 epitope |
TW201302793A (zh) | 2010-09-03 | 2013-01-16 | Glaxo Group Ltd | 新穎之抗原結合蛋白 |
EP2635604B1 (en) | 2010-11-01 | 2016-11-30 | Symphogen A/S | Pan-her antibody composition |
WO2012143524A2 (en) | 2011-04-20 | 2012-10-26 | Genmab A/S | Bispecific antibodies against her2 and cd3 |
AU2012318541B2 (en) * | 2011-10-06 | 2018-04-12 | Aveo Pharmaceuticals, Inc. | Predicting tumor response to anti-ERBB3 antibodies |
US20130095172A1 (en) | 2011-10-14 | 2013-04-18 | Genentech, Inc. | Uses for and article of manufacture including her2 dimerization inhibitor pertuzumab |
AR094403A1 (es) | 2013-01-11 | 2015-07-29 | Hoffmann La Roche | Terapia de combinación de anticuerpos anti-her3 |
JP6602746B2 (ja) | 2013-03-15 | 2019-11-06 | カポン、ダニエル・ジェイ. | 非ペプチジル結合を含むハイブリッド免疫グロブリン |
CA3071678A1 (en) | 2013-04-16 | 2014-10-23 | Genentech,Inc. | Pertuzumab variants and evaluation thereof |
WO2015100459A2 (en) | 2013-12-27 | 2015-07-02 | Merrimack Pharmaceuticals, Inc. | Biomarker profiles for predicting outcomes of cancer therapy with erbb3 inhibitors and/or chemotherapies |
SI3701971T1 (sl) | 2014-03-14 | 2023-01-31 | Biomolecular Holdings LLC, | Spojine, uporabne v pripravi hibridnega imunoglobulina, ki vsebuje nepeptidilno vezavo |
SG10201809411PA (en) | 2014-04-25 | 2018-11-29 | Genentech Inc | Methods of treating early breast cancer with trastuzumab-mcc-dm1 and pertuzumab |
US10208130B2 (en) * | 2015-05-29 | 2019-02-19 | Expression Pathology, Inc. | Quantifying Her2 protein for optimal cancer therapy |
CN107614015A (zh) | 2015-05-30 | 2018-01-19 | 豪夫迈·罗氏有限公司 | 治疗her2阳性局部晚期或先前未治疗的转移性乳腺癌的方法 |
US10184006B2 (en) | 2015-06-04 | 2019-01-22 | Merrimack Pharmaceuticals, Inc. | Biomarkers for predicting outcomes of cancer therapy with ErbB3 inhibitors |
WO2017087280A1 (en) | 2015-11-16 | 2017-05-26 | Genentech, Inc. | Methods of treating her2-positive cancer |
GB201611580D0 (en) * | 2016-07-01 | 2016-08-17 | Aslan Pharmaceuticals Pte Ltd | Method |
EP3534948A1 (en) | 2016-11-04 | 2019-09-11 | Genentech, Inc. | Treatment of her2-positive breast cancer |
CN110099926A (zh) | 2016-12-28 | 2019-08-06 | 豪夫迈·罗氏有限公司 | 晚期her2表达性癌症的治疗 |
CR20190376A (es) | 2017-01-17 | 2019-11-20 | Genentech Inc | Formulaciones de anticuerpos de her2 subcutáneas |
EP3589661B1 (en) | 2017-03-02 | 2023-11-01 | Genentech, Inc. | Adjuvant treatment of her2-positive breast cancer |
TW201902509A (zh) | 2017-04-24 | 2019-01-16 | 美商建南德克公司 | Erbb2/her2突變 |
Family Cites Families (49)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4968603A (en) * | 1986-12-31 | 1990-11-06 | The Regents Of The University Of California | Determination of status in neoplastic disease |
US5824311A (en) * | 1987-11-30 | 1998-10-20 | Trustees Of The University Of Pennsylvania | Treatment of tumors with monoclonal antibodies against oncogene antigens |
US5720937A (en) * | 1988-01-12 | 1998-02-24 | Genentech, Inc. | In vivo tumor detection assay |
JP3040121B2 (ja) * | 1988-01-12 | 2000-05-08 | ジェネンテク,インコーポレイテッド | 増殖因子レセプターの機能を阻害することにより腫瘍細胞を処置する方法 |
US5183884A (en) * | 1989-12-01 | 1993-02-02 | United States Of America | Dna segment encoding a gene for a receptor related to the epidermal growth factor receptor |
IL101943A0 (en) * | 1991-05-24 | 1992-12-30 | Genentech Inc | Structure,production and use of heregulin |
CA2103059C (en) * | 1991-06-14 | 2005-03-22 | Paul J. Carter | Method for making humanized antibodies |
WO1994004679A1 (en) * | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
US6800738B1 (en) * | 1991-06-14 | 2004-10-05 | Genentech, Inc. | Method for making humanized antibodies |
US6685940B2 (en) * | 1995-07-27 | 2004-02-03 | Genentech, Inc. | Protein formulation |
US6267958B1 (en) * | 1995-07-27 | 2001-07-31 | Genentech, Inc. | Protein formulation |
US5783186A (en) * | 1995-12-05 | 1998-07-21 | Amgen Inc. | Antibody-induced apoptosis |
ZA9811162B (en) * | 1997-12-12 | 2000-06-07 | Genentech Inc | Treatment with anti-ERBB2 antibodies. |
AU765003B2 (en) * | 1998-03-27 | 2003-09-04 | Genentech Inc. | Apo-2 ligand-anti-her-2 antibody synergism |
AU760048B2 (en) * | 1998-05-06 | 2003-05-08 | Genentech Inc. | Protein purification by ion exchange chromatography |
US6573043B1 (en) * | 1998-10-07 | 2003-06-03 | Genentech, Inc. | Tissue analysis and kits therefor |
EP1187632B1 (en) * | 1999-05-14 | 2008-12-03 | Genentech, Inc. | TREATMENT WITH ANTI-ErbB2 ANTIBODIES |
US20040013667A1 (en) * | 1999-06-25 | 2004-01-22 | Genentech, Inc. | Treatment with anti-ErbB2 antibodies |
CN100340575C (zh) * | 1999-06-25 | 2007-10-03 | 杰南技术公司 | 人源化抗ErbB2抗体及其在制备药物中的应用 |
US20030086924A1 (en) * | 1999-06-25 | 2003-05-08 | Genentech, Inc. | Treatment with anti-ErbB2 antibodies |
AU779209B2 (en) * | 1999-06-25 | 2005-01-13 | Genentech Inc. | Treating prostate cancer with anti-ErbB2 antibodies |
US6949245B1 (en) * | 1999-06-25 | 2005-09-27 | Genentech, Inc. | Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies |
US7041292B1 (en) * | 1999-06-25 | 2006-05-09 | Genentech, Inc. | Treating prostate cancer with anti-ErbB2 antibodies |
TR200200472T2 (tr) * | 1999-08-27 | 2002-06-21 | Genentech, Inc. | Anti-Erb B2 antikorları ile tedavi için dozajlar |
US7097840B2 (en) * | 2000-03-16 | 2006-08-29 | Genentech, Inc. | Methods of treatment using anti-ErbB antibody-maytansinoid conjugates |
CN102698265A (zh) * | 2000-05-19 | 2012-10-03 | 杰南技术公司 | 用于提高对ErbB 拮抗剂癌症治疗的有效应答可能性的基因检测试验 |
US20030190689A1 (en) * | 2002-04-05 | 2003-10-09 | Cell Signaling Technology,Inc. | Molecular profiling of disease and therapeutic response using phospho-specific antibodies |
US20040248151A1 (en) * | 2002-04-05 | 2004-12-09 | Ventana Medical Systems, Inc. | Method for predicting the response to HER2-directed therapy |
PT2263691E (pt) * | 2002-07-15 | 2012-11-12 | Hoffmann La Roche | Tratamento de cancro com o anticorpo anti-erbb2 monoclonal humanizado recombinante 2c4 (rhumab 2c4) |
US20040013297A1 (en) * | 2002-07-18 | 2004-01-22 | Roger Lo | Method for performing color gamut compression |
ATE437962T1 (de) * | 2002-10-01 | 2009-08-15 | Epigenomics Ag | Verfahren für die behandlung von proliferativen erkrankungen von brustzellen |
EP1570080A4 (en) * | 2002-11-15 | 2006-03-01 | Genomic Health Inc | GENE EXPRESSION PROFILING OF EGFR-POSITIVE CANCER DISEASE |
AU2003295798B2 (en) * | 2002-11-21 | 2009-09-10 | Genentech, Inc. | Therapy of non-malignant diseases or disorders with anti-ErbB2 antibodies |
US20040231909A1 (en) * | 2003-01-15 | 2004-11-25 | Tai-Yang Luh | Motorized vehicle having forward and backward differential structure |
EP3470535B1 (en) * | 2003-06-24 | 2020-04-01 | Genomic Health, Inc. | Prediction of likelihood of cancer recurrence |
EP1737489B1 (en) * | 2004-04-08 | 2012-01-11 | David B Agus | ErbB2 antagonists for tumor pain therapy |
GT200500155A (es) * | 2004-06-16 | 2006-05-15 | Terapia del càncer resistente al platino | |
KR20180091967A (ko) * | 2004-07-22 | 2018-08-16 | 제넨테크, 인크. | Her2 항체 조성물 |
JO3000B1 (ar) * | 2004-10-20 | 2016-09-05 | Genentech Inc | مركبات أجسام مضادة . |
WO2006063042A2 (en) * | 2004-12-07 | 2006-06-15 | Genentech, Inc. | Selecting patients for therapy with a her inhibitor |
KR20170134771A (ko) * | 2005-01-21 | 2017-12-06 | 제넨테크, 인크. | Her 항체의 고정 용량 투여법 |
KR101253576B1 (ko) * | 2005-02-23 | 2013-04-11 | 제넨테크, 인크. | Her 이량체화 억제제를 이용한 암 환자에서의 질환진행까지의 시간 또는 생존의 연장 |
TW200642695A (en) * | 2005-03-08 | 2006-12-16 | Genentech Inc | Methods for identifying tumors responsive to treatment with her dimerization inhibitors (HDIs) |
JP2006316040A (ja) * | 2005-05-13 | 2006-11-24 | Genentech Inc | Herceptin(登録商標)補助療法 |
PE20070207A1 (es) * | 2005-07-22 | 2007-03-09 | Genentech Inc | Tratamiento combinado de los tumores que expresan el her |
US7700299B2 (en) * | 2005-08-12 | 2010-04-20 | Hoffmann-La Roche Inc. | Method for predicting the response to a treatment |
TW200812615A (en) * | 2006-03-22 | 2008-03-16 | Hoffmann La Roche | Tumor therapy with an antibody for vascular endothelial growth factor and an antibody for human epithelial growth factor receptor type 2 |
US20080038271A1 (en) * | 2006-06-05 | 2008-02-14 | Amler Lukas C | Extending survival of cancer patients with elevated levels of EGF or TGF-alpha |
SG174090A1 (en) * | 2006-08-21 | 2011-09-29 | Hoffmann La Roche | Tumor therapy with an anti-vegf antibody |
-
2005
- 2005-12-06 WO PCT/US2005/044247 patent/WO2006063042A2/en active Application Filing
- 2005-12-06 EP EP05853228A patent/EP1825001A2/en not_active Withdrawn
- 2005-12-06 KR KR1020077012834A patent/KR20070085855A/ko not_active Application Discontinuation
- 2005-12-06 US US11/295,229 patent/US20060121044A1/en not_active Abandoned
- 2005-12-06 JP JP2007545584A patent/JP2008523073A/ja active Pending
- 2005-12-06 CA CA002587519A patent/CA2587519A1/en not_active Abandoned
- 2005-12-06 BR BRPI0518086-4A patent/BRPI0518086A/pt not_active IP Right Cessation
- 2005-12-06 RU RU2007125644/13A patent/RU2007125644A/ru not_active Application Discontinuation
- 2005-12-06 AU AU2005314127A patent/AU2005314127A1/en not_active Abandoned
- 2005-12-06 ZA ZA200704796A patent/ZA200704796B/xx unknown
- 2005-12-06 CN CNA2005800478629A patent/CN101115849A/zh active Pending
- 2005-12-06 MX MX2007006529A patent/MX2007006529A/es not_active Application Discontinuation
- 2005-12-07 AR ARP050105126A patent/AR051524A1/es not_active Application Discontinuation
-
2007
- 2007-07-05 NO NO20073487A patent/NO20073487L/no not_active Application Discontinuation
-
2008
- 2008-05-01 US US12/113,802 patent/US20080317753A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
ZA200704796B (en) | 2008-11-26 |
NO20073487L (no) | 2007-09-05 |
CN101115849A (zh) | 2008-01-30 |
BRPI0518086A (pt) | 2008-10-28 |
JP2008523073A (ja) | 2008-07-03 |
EP1825001A2 (en) | 2007-08-29 |
MX2007006529A (es) | 2007-06-22 |
RU2007125644A (ru) | 2009-01-20 |
WO2006063042A3 (en) | 2007-02-08 |
CA2587519A1 (en) | 2006-06-15 |
US20060121044A1 (en) | 2006-06-08 |
AU2005314127A1 (en) | 2006-06-15 |
US20080317753A1 (en) | 2008-12-25 |
KR20070085855A (ko) | 2007-08-27 |
WO2006063042A2 (en) | 2006-06-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR051524A1 (es) | Seleccion de pacientes para una terapia con un inhibidor de her | |
ES2422739T3 (es) | Composición para el diagnóstico, prevención o tratamiento de enfermedades relacionadas con células que expresan IL-8 o GRO-, que comprende MSC de UCB | |
AR054426A1 (es) | Uso de un inhibidor de la dimerizacion de receptores tirosina quinasas her para la manufactura de un medicamento para alargar el tiempo hasta l a progresion de la enfermedad o la supervivencia de los pacientes de cancer | |
ECSP17025787A (es) | Uso de paneles de genes mutantes de fgfr en la identificación de pacientes con cáncer que responderán al tratamiento con un inhibidor de fgfr | |
ECSP12012024A (es) | Terapia combinada para el tratamiento del cáncer y ensayos de diagnóstico relacionados | |
AR100225A2 (es) | Anticuerpos anti-factor d humanizados y usos de los mismos | |
CY1116764T1 (el) | Χρηση στρωματικων βλαστοκυτταρων λαμβανομενων απο λιπωδη ιστο στην θεραπεια συριγγιου | |
CY1110889T1 (el) | C-αρυλο γλυκοζιτικοι sglt2 αναστολεις και μεθοδος για την παραγωγη τους | |
BR112014009276A2 (pt) | uso de inibidores de tirosina quinase de bruton (btk) | |
UY32812A (es) | Anticuerpos humanos de alta afinidad para angiopoyetina -2 humana. | |
EA201100335A8 (ru) | Производные пурина для применения при лечении связанных с fab заболеваний | |
CL2008002793A1 (es) | Compuestos derivados de amidas sustituidas, inhibidores de la actividad de btk; composicion farmaceutica que los comprende; utiles en el tratamiento del cancer, trastornos oseos, enfermedades autoinmunes, entre otras | |
AR061230A1 (es) | Prolongacion de la supervivencia de pacientes con cancer con niveles elevados de egf o tgf-alfa | |
AR053272A1 (es) | Determinacion de responsivos a la quimioterapia | |
CL2009001476A1 (es) | Compuestos derivados de 2,4-diamin-n2-fenil pirimidina sustituidos, mediadores de la inhibicion de igf-1r; composicion farmaceutica que comprende a dichos compuestos; y su uso en el tratamiento de enfermedades autoinmune, por trasplante, infecciosas o un trastorno proliferativo celular. | |
BRPI0518104A (pt) | métodos de tratamento de cáncer, artigo industrializado e uso de um anticorpo her | |
NZ603245A (en) | Therapeutic applications of activation of human antigen-presenting cells through dectin-1 | |
ES2570631T3 (es) | Procedimiento de determinación de la apolipoproteína AII para el diagnóstico in vitro del cáncer colorrectal | |
AR052165A1 (es) | Tratamiento de hepatitis c en la poblacion asiatica | |
UY30587A1 (es) | Benzoxazoles y oxazolopiridinas que son utiles como inhibidores de las cinasa s janus | |
CL2012002542A1 (es) | Proceso in vitro para la determinación rápida del estado de infección de pacientes con infección por mycobacterium tuberculosis a partir de sangre entera en términos de tuberculosis activa o latente, que comprende las etapas de (i) estimular una célula t antígeno específico, y (ii) determinar un perfil de citosinas a partir de tanto la producción intracelular de inf-gamma como de il-2. | |
AR092899A1 (es) | Uso de masitinib para el tratamiento del cancer en subpoblaciones de pacientes identificados que utilizan factores de prediccion | |
CO2022000481A2 (es) | Inhibidores de enzimas | |
DOP2015000162A (es) | Anticuerpos anti-lamp1 y conjugados anticuerpo fármaco, y usos de éstos | |
BR112022007932A2 (pt) | Métodos para tratamento de leucemia e uso de uma assinatura de células-tronco leucêmicas para predizer sensibilidade clínica a terapias |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Abandonment or withdrawal |